Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)19.89
  • Today's Change-0.08 / -0.40%
  • Shares traded775.78k
  • 1 Year change+4.63%
  • Beta0.8284
Data delayed at least 15 minutes, as of Sep 19 2024 16:39 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments693706737
Total Receivables, Net1,8571,5851,497
Total Inventory1,3151,003915
Prepaid expenses------
Other current assets, total643637611
Total current assets4,5083,9313,760
Property, plant & equipment, net1,3561,2331,203
Goodwill, net4,6034,6034,603
Intangibles, net533649651
Long term investments------
Note receivable - long term------
Other long term assets250272464
Total assets12,05810,95510,681
LIABILITIES
Accounts payable1,3141,1321,382
Accrued expenses1,3891,1881,021
Notes payable/short-term debt000
Current portion long-term debt/capital leases9.008.009.00
Other current liabilities, total206184185
Total current liabilities2,9182,5122,597
Total long term debt8,7518,9059,125
Total debt8,7608,9139,134
Deferred income tax47194.00
Minority interest------
Other liabilities, total412411463
Total liabilities12,12811,84712,189
SHAREHOLDERS EQUITY
Common stock3.003.003.00
Additional paid-in capital25--0
Retained earnings (accumulated deficit)443(331)(998)
Treasury stock - common------
Unrealized gain (loss)----0
Other equity, total(541)(564)(513)
Total equity(70)(892)(1508)
Total liabilities & shareholders' equity12,05810,95510,681
Total common shares outstanding256254254
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.